Pull to refresh
Logo
Daily Brief
Following Why Sign Up
Nicholas Turner

Nicholas Turner

Principal investigator, SERENA-6 trial

Appears in 1 story

Notable Quotes

We have shown for the first time that ctDNA monitoring can identify early signs of resistance and prompt a change in therapy that prolongs disease control.

Stories

FDA panel weighs blood-test-guided early drug switch for breast cancer

New Capabilities

Lead author of the trial publication; presenter at ASCO 2025 plenary

For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.

Updated 2 hours ago